TINY VC equity investment in Evolved Nanomaterials:
Evolved Nanomaterials takes in its first VC round
Mass High Tech:
The Journal of New England Technology - March 13, 2006
by Dyke Hendrickson
Senior staff writer
Evolved Nanomaterial Sciences Inc. of Cambridge has closed on a Series A round of $3.3 million.
"We're very pleased with the funding," said Robert Pucciariello, chief executive of ENS. "We have a lot of work to do, and this will help us move forward."
ENS was founded in 2002 by Regina Valluzzi, who is now chief scientific officer.
It employs 10, and is a nascent advanced-materials enterprise focusing on the discovery, fabrication and integration of biopolymers.
The company is targeting the field of chiral separations science. Industry observers say that pharmaceutical companies could use chiral separation in the development of new medications.
Using nanotechnology-enhanced approaches, ENS has "expanded the chemical range of chiral chromatography to include low molecular weight compounds, commonly used in chiral synthesis, crystallographic resolution and analysis," company officials say.
The company's name reflects that its core technology is focused on nanomaterials, which are created from biopolymers that are at the nanometer scale. A nanometer is one-billionth of a meter.
ENS officials say the core technology platform can be the basis for a number of advanced applications, including chiral separations, filtration membranes, ion scavenging and tissue engineering.
Providing the funding was Harris & Harris Group Inc. of New York. Harris & Harris officials describe the firm as a venture capital company investing in "tiny" technology, including nanotechnology, microsystems and microelectromechanical systems technology.
It is a public company, with a Nasdaq symbol of TINY.
dhendrickson@masshightech.com | 617-241-4330 |
